Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894516 | 0.87 | TYMS (0.33) | TYMS | |
| SCHEMBL14296961 | 0.87 | TYMS (0.33) | TYMS | |
| SCHEMBL27316637 | 0.86 | TYMS (0.34) | TYMSMEN1POLBKMT2AAR | |
| SCHEMBL13590977 | 0.81 | TYMS (0.33) | TYMSMEN1POLBKMT2AAR | |
| SCHEMBL13010657 | 0.80 | TDP1 (0.40) | TYMSALOX15TDP1MEN1POLB | |
| SCHEMBL24166827 | 0.79 | TYMS (0.42) | TYMSALOX15TDP1MEN1POLB | |
| SCHEMBL4324585 | 0.78 | TYMS (0.41) | TYMSALOX15TDP1MEN1POLB | |
| SCHEMBL32670397 | 0.78 | TYMS (0.41) | TYMSALOX15TDP1MEN1POLB | |
| SCHEMBL1188564 | 0.78 | TYMS (0.41) | TYMSALOX15TDP1MEN1POLB | |
| SCHEMBL29580210 | 0.78 | TYMS (0.41) | TYMSALOX15TDP1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158620-A1 | COMPOUND WITH BRANCHING ALKYL CHAINS, METHOD FOR PREPARING THE SAME, AND USE THEREOF IN PHOTOELECTRIC DEVICE | BOE TECHNOLOGY GROUP CO LTD (CN) | 2017-06-08 | — | — | US | disclosed |
| US-9611216-B2 | Compound with branching alkyl chains, method for preparing the same, and use thereof in photoelectric device | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2017-04-04 | — | — | US | disclosed |
| US-20160002164-A1 | COMPOUND WITH BRANCHING ALKYL CHAINS, METHOD FOR PREPARING THE SAME, AND USE THEREOF IN PHOTOELECTRIC DEVICE | BOE TECHNOLOGY GROUP CO LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-9209405-B2 | Compound with branching alkyl chains, method for preparing the same, and use thereof in photoelectric device | PEKING UNIVERSITY (CN) | 2015-12-08 | — | — | US | disclosed |
| US-20140011973-A1 | COMPOUND WITH BRANCHING ALKYL CHAINS, METHOD FOR PREPARING THE SAME, AND USE THEREOF IN PHOTOELECTRIC DEVICE | PEKING UNIVERSITY (CN) | 2014-01-09 | — | — | US | disclosed |
| US-20120091449-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158620-A1 | COMPOUND WITH BRANCHING ALKYL CHAINS, METHOD FOR PREPARING THE SAME, AND USE THEREOF IN PHOTOELECTRIC DEVICE | PCNA, EPCAM, DNMT1 | TYMS 571/4885ALOX15 539/4885TDP1 1889/4885 |
| US-20160002164-A1 | COMPOUND WITH BRANCHING ALKYL CHAINS, METHOD FOR PREPARING THE SAME, AND USE THEREOF IN PHOTOELECTRIC DEVICE | OR10J3, EPCAM, PCNA | TYMS 479/4885ALOX15 328/4885TDP1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.